Herpes zoster
Conditions
Interventions
investigational material(s)
Generic name etc : AK-120
INN of investigational material :
Therapeutic category code : 625 Anti-virus agents
Dosage and Administration for Investigational material : Oral
Sponsors
ASAHIKASEI PHARMA CORPORATION
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria 1) patients diagnosed with herpes zoster; 2) patients in whom the study drug can be administered within 72 hours of onset of the zoster rash; 3) patients in whom edematous erythema is observed before the development of vesicles are noted; 4) patients aged 20 to 80 years; 5) patient can be either male or female. Exclusion criteria 1) patients with severe herpes zoster in whom sufficient therapeutic benefit cannot be anticipated from oral medication; 2) patients whose clinical conditions are diagnosed as evidencing either immunodeficiency or depressed immune functions; 3) patients with a past history of herpes zoster; 4) patients whose lesions have started to crust.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy, safety | — |
Outcome results
None listed